Drugs / Brivanib alaninate
Brivanib alaninate
also known as
Alaninate de brivanib · Alaninato de brivanib · BMS-582664 · BMS-582664-02 · Brivanib l-alanine ester
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00798252 | Mar 2009 → May 2015 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00300027 | Apr → Dec 2006 | digestive system neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brivanib alaninate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00798252 ↗ |
| Known as | Alaninate de brivanib | ChEMBL registry synonym — accepted as the source's own label CHEMBL270995 ↗ |
| Known as | Alaninato de brivanib | ChEMBL registry synonym — accepted as the source's own label CHEMBL270995 ↗ |
| Known as | BMS-582664 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00300027 ↗ |
| Known as | BMS-582664-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL270995 ↗ |
| Known as | Brivanib l-alanine ester | ChEMBL registry synonym — accepted as the source's own label CHEMBL270995 ↗ |
| Modality | Small molecule | — CHEMBL270995 ↗ |
| Route | Oral | “Tablets, Oral” NCT00798252 ↗ |